Hyper-Cvad Plus Epratuzumab As Salvage Regimen For Younger Relapsed/Refractory Cd22+B Acute Lymphoblastic Leukemia (All) Patients: Results Of The Phase 2 Prospective Cheprall Study

Purpose: Hyper-CVAD developed by the MD Anderson group a few years ago, is one of the standard salvage regimen used for younger relapsed/refractory ALL patients. Recently, targeted therapies using monoclonal antibodies directed against such surface antigens as CD19, CD20 or CD22 have allowed to obtain complete remission (CR) in B ALL expressing these markers. We hypothesized that combining Hyper-CVAD and an anti-CD22 monoclonal antibody could improve the response of such patients.